9097 POSTER

Conformal radiotherapy in radical treatment of stage III non-small cell lung cancer (nsclc)

J.L. Monroy Anton[1], M. Soler Tortosa[1], M. Lopez Muñoz[1], A.V. Navarro Bergada[1], M.A. Estornell Gualde[1], A.L. Revert Vidal[1]. [1]*Hospital La Ribera, Radiation Oncology, Alzira (Valencia), Spain*

Background: Radiotherapy alone or combined with chemotherapy is standard treatment for stage III non-small cell lung (NSCLC) cancer. Conventional schedules of radiotherapy reach doses higher than 40 Gy trying to offer a better survival in these patients. Our objective was to evaluate the overall survival in a population of patients that received 3D conformal external radiotherapy with conventional doses and fractionation schedules.
Materials and Methods: Between 2002 and 2006 75 patients with NSCLC stage III (A/B) were treated in our institution with external radiotherapy (virtual simulation and 3D planning). None of the patients underwent surgery before or after radiotherapy. 70 patients received different schemes of chemotherapy. Aged ranged between 43−83 years. Radiotherapy treatment planning was developed with isocentric and multiple field technique. Total doses were from 42 to 65 Gy, fractionation 1.8−2.0 Gy. Chemotherapy was also administered in 68 of them.
Results: At the end of the study (84 months of follow-up), only 6 patients still alive (8%). Mean survival was 16 months; median, 13m. The value more frequent was 7 months. Survival between 0−6 months was 29%; 6−12 m: 16%; 12−18m: 28%; 18−24m: 12%; >24 m: 15%. 17 patients received doses between 42−50 Gy, with mean survival: 19 m (median: 15); 44 patients, doses = 50−60 Gy, mean survival: 13 (median: 11); 13 patients, doses higher than 60 Gy, mean survival: 25m (median: 21). These results were not comparable because of the different and little number of patients of the groups.
Conclusions: Radical radiation treatment with high doses and conventional fractionation in NSCLC stage III in our institution gives a survival less than 2 years in the majority of patients. We could not observe differences in survival according different total doses because of the little number of patients. Further studies and more patients analyzed could give us more information about this question in order to increase these total doses.

9098 POSTER

Role of postoperative radiotherapy for advanced stage non-small cell lung cancer

M. Kim[1], H. Wu[1], C. Park[1], D. Heo[2], Y. Kim[2], D. Kim[2], S. Lee[2], J. Kim[3], Y. Kim[3], C. Kang[3]. [1]*Seoul National University College of Medicine, Radiation oncology, Seoul, Korea;* [2]*Seoul National University College of Medicine, Internal medicine, Seoul, Korea;* [3]*Seoul National University College of Medicine, Thoracic surgery, Seoul, Korea*

Purpose: To evaluate outcomes and prognostic factors of postoperative radiotherapy (PORT) for patients with advanced stage non-small-cell lung cancer (NSCLC) at our institution.
Methods and Materials: From 2000 to 2007, 88 patients had PORT after curative operation for pathologic stage III NSCLC at our institution. At diagnosis, median age was 59 years (range 31−81). There were 80 patients in stage IIIA and 8 patients in stage IIIB. Preoperative nodal stage was as follows: 45 patients in N0, 8 patients in N1, and 35 patients in N2. Among 35 preoperative N2 diseases, 21 patients had single station mediastinal lymph node (LN) metastasis. Eighty three patients had postoperative N2 disease, and 56 patients had single station mediastinal LN metastasis. Surgical types included pneumonectomy (N = 14), bilobectomy (N = 14), or lobectomy (N = 60) with mediastinal lymph node dissection (MLND) (N = 73) or multi-level mediastinal lymph node sampling (N = 15). Seventy six patients had received radiotherapy using conventional technique. Initially 23.4−56 Gy (median 45 Gy) was delivered to mediastinum and bronchial stump area and then tumor bed received additional 3.6−23.4 Gy (median 9 Gy). Thirty six patients had received chemotherapy; 17 patients with adjuvant, 5 patients with neoadjuvant and 14 patients with both.
Results: Median survival was 54 months. 5-yr overall survival (OS) and disease free survival (DFS) rates were 45% and 38% respectively. MLND, total radiation dose greater than 54 Gy and adjuvant chemotherapy did not affect OS (p-value = 0.9525, 0.4160, and 0.8956, respectively). Single station mediastinal LN metastasis is associated with increase in DFS (p-value = 0.0014). 5-yr loco-regional recurrence free survival (LRFS) and distant-metastasis free survival (DMFS) rates were 86% and 48% respectively. Fifty-one relapses occurred at following site: 10 in loco-regional, 11 in lung, 11 in bone, 10 in brain, 4 in kidney, adrenal gland, 3 in non-regional LN, and 2 in liver. Of 10 loco-regional relapses, 6 relapses occurred in radiation field. Total radiation dose greater than 54 Gy did not reduce loco-regional recurrence (p-value = 0.6376). Administration of chemotherapy had no significant effect on distant metastasis (p-value = 0.5583).
Conclusion: PORT after curative operation for resectable advanced stage NSCLC may reduce loco-regional recurrence and increase overall survival. However, criteria for resectability of stage III disease should be further defined because of heterogenous presentation of advanced stage NSCLC. Further efforts are necessary to reduce distant metastasis.

9099 POSTER

Is there any future of prophylactic cranial irradiation in adenocarcinoma of the lung?

M. Ozguroglu[1], H. Turna[1], M. Sevinc[1], S. Karaaslan[1], U.R. Gursu[1]. [1]*Istanbul University Cerrahpasa Medical Faculty, Medical Oncology, Istanbul, Turkey*

Background: In this study, we aimed to evaluate the rate of cranial metastases in nonsmall cell-nonsquamous lung cancer patients(NSCLC-NS), refractory to first line platinum based therapy, comparing with small cell lung cancer(SCLC) patients. We argued the role of prophylactic cranial irradiation, especially in patients with adenocarcinoma of the lung that has a high rate of cranial metastasis.
Materials and Methods: Patients who have been treated with a diagnosis of NSCLC-NS and SCLC in our department of oncology between January and December 2008 were retrospectively analyzed. Data have been collected from the patient charts and analyzed by SPSS.
Results: There were 39 patients with NSCLC-NS and 66 patients wih SCLC. Mean ages were 58 and 62, respectively. Most of the caes of NSCLC-NS were adenocarcinoma of the lung. At the time of diagnosis, none of the cases with NSCLC-NS had cranial metastases, while 22.7% (n = 15) of patients with SCLC had cranial metastases at the time of presentation. Howvever, following failure of first line platinum based therapy, cranial metastases have been detected in 35.9% (n = 14) of asymptomatic NSCLC-NS cases. The rate of cranial metastases was even higher than SCLC cases, who had cranial metastases in 22.7% of cases at the time of diagnosis and developed cranial metasases in only one case (3.6%) after failure of first line therapy.
Conclusion: In this single center study, it seems that even though they were asymptomatic, we detected very high rate of cranial metastases at the time of progression in NSCLC-NS, especially in patients with adenocarcinoma of the lung. We can argue that like SCLC, prophylactic cranial irradiation may be part of standard treatment in patients with NSCLC-NS cases, with adenocarcinoma subtype, who progressed under firstline platinum based treatment.

9100 POSTER

Induction Docetaxel (D) and Cisplatin (C) plus concurrent Thoracic Radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC) - a Galician Lung Cancer Group study

J. Casal Rubio[1], S. Vazquez Estevez[2], M. Lázaro Quintela[3], B. Campos Balea[2], U. Anido Herranz[4], G. Huidobro Vence[5], A. Gomez Caamaño[6], M. Caeiro Muñoz[7], J.L. Firvida Perez[8], M. Amenedo Gancedo[9]. [1]*Hospital do Meixoeiro, Oncoloxia Medica, Vigo, Spain;* [2]*Hospital Xeral-Calde, Oncoloxia Medica, Lugo, Spain;* [3]*Hospital Xeral-Cies, Oncoloxia Medica, Vigo, Spain;* [4]*Hospital Clínico Universitario, Oncoloxia Medica, Santiago, Spain;* [5]*Hospital Meixoeiro, Oncoloxia Medica, Vigo, Spain;* [6]*Hospital Clinico Universitario, Oncoloxia Radioterapica, Santiago, Spain;* [7]*Hospital Meixoeiro, Oncoloxia Radioterapica, Vigo, Spain;* [8]*Hospital Cristal Piñor, Oncoloxia Medica, Ourense, Spain;* [9]*Centro Oncolóxico de Galiza, Oncoloxia Medica, A'Coruña, Spain*

Background: Standard treatment of stage III NSCLC remains concurrent chemoradiation, although a clearly superior régimen has not been identified. D has been shown to possess good single agent activity against NSCLC as well as radiosensiziting properties, both alone and sinergisitically with C. The aim of our study is to evaluate the feasibility of induction chemotherapy with D-C followed by biweekly D-C and concurrent TRT.
Methods: 65 patients (p) with inoperable locally advanced NSCLC, stage IIIAN2/IIIB (no pleural T4), were included in a phase II study with induction chemotherapy consisting of three cycles of D 75 mg/m^2 on day 1 and C 40 mg/m^2 days 1−2 every 3 weeks and, if no surgery, then received concurrent TRT with D 30 mg/m^2 and C 30 mg/m^2 every 2 weeks for four courses, during conformal TRT (60−66 Gys, 180 cGy/day). The primary objective: overall survival; secondary: progression free survival, response rate (RR) and toxicity. Median follow-up: 8.8 months.
Results: The p characteristics were: mean age 61.6 years (44−75); male/female 61/4; ECOG PS 0/1 in 15/50 p; squamous/adeno/large cell carcinoma: 53.8%/23.1%/23.1%; stage IIIAN2 16 p (24.7%) and stage IIIB